Alkermes plc Q3 2025 Financial Results

Alkermes plc reported its financial results for the third quarter of 2025, with total revenues of $394.2 million, a 4.3% increase compared to the same period in 2024. The company achieved a GAAP net income of $82.8 million, with diluted GAAP earnings per share of $0.49. Key drivers of revenue growth included strong performance in proprietary products such as VIVITROL®, ARISTADA®, and LYBALVI®, which saw net sales of $121.1 million, $98.1 million, and $98.2 million, respectively. Alkermes also raised its financial expectations for 2025, projecting total revenues between $1,430 million and $1,490 million, and GAAP net income between $230 million and $250 million. The company highlighted progress in its development pipeline, particularly in its orexin 2 receptor agonist program, and announced the proposed acquisition of Avadel Pharmaceuticals as a potential growth driver.